Literature DB >> 35701723

Striatal Dopaminergic Depletion Pattern Reflects Pathological Brain Perfusion Changes in Lewy Body Diseases.

Yu Iwabuchi1, Tohru Shiga2, Masashi Kameyama3,4, Raita Miyazawa3, Morinobu Seki5, Daisuke Ito6, Hiroyuki Uchida7, Hajime Tabuchi7, Masahiro Jinzaki3.   

Abstract

PURPOSE: In Lewy body diseases (LBD), various symptoms occur depending on the distribution of Lewy body in the brain, and the findings of brain perfusion and dopamine transporter single-photon emission computed tomography (DAT-SPECT) also change accordingly. We aimed to evaluate the correlation between brain perfusion SPECT and quantitative indices calculated from DAT-SPECT in patients with LBD. PROCEDURES: We retrospectively enrolled 35 patients with LBD who underwent brain perfusion SPECT with N-isopropyl-p-[123I] iodoamphetamine and DAT-SPECT with 123I-ioflupane. Mini-mental state examination (MMSE) data were also collected from 19 patients. Quantitative indices (specific binding ratio [SBR], putamen-to-caudate ratio [PCR], and caudate-to-putamen ratio [CPR]) were calculated using DAT-SPECT. These data were analysed by the statistical parametric mapping procedure.
RESULTS: In patients with LBD, decreased PCR index correlated with hypoperfusion in the brainstem (medulla oblongata and midbrain) (uncorrected p < 0.001, k > 100), while decreased CPR index correlated with hypoperfusion in the right temporoparietal cortex (family-wise error corrected p < 0.05), right precuneus (uncorrected p < 0.001, k > 100), and bilateral temporal cortex (uncorrected p < 0.001, k > 100). However, there was no significant correlation between decreased SBR index and brain perfusion. Additionally, the MMSE score was correlated with hypoperfusion in the left temporoparietal cortex (uncorrected p < 0.001).
CONCLUSIONS: This study suggests that regional changes in striatal 123I-ioflupane accumulation on DAT-SPECT are related to brain perfusion changes in patients with LBD.
© 2022. The Author(s).

Entities:  

Keywords:  123I-FP-CIT; Parkinsonian syndrome; Parkinsonism; SPM; α-synuclein; α-synucleinopathy

Year:  2022        PMID: 35701723     DOI: 10.1007/s11307-022-01745-x

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  46 in total

1.  Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease.

Authors:  Yasunori Mito; Ichiro Yabe; Hiroaki Yaguchi; Chika Sato; Toshiki Takei; Satoshi Terae; Yasutaka Tajima
Journal:  Clin Neurol Neurosurg       Date:  2020-05-26       Impact factor: 1.876

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia.

Authors:  Pekka Jokinen; Noora Scheinin; Sargo Aalto; Kjell Någren; Nina Savisto; Riitta Parkkola; Johanna Rokka; Merja Haaparanta; Matias Röyttä; Juha O Rinne
Journal:  Parkinsonism Relat Disord       Date:  2010-09-25       Impact factor: 4.891

4.  Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

Authors:  Bernard Ravina; Kenneth Marek; Shirley Eberly; David Oakes; Roger Kurlan; Alberto Ascherio; Flint Beal; James Beck; Emily Flagg; Wendy R Galpern; Jennifer Harman; Anthony E Lang; Michael Schwarzschild; Caroline Tanner; Ira Shoulson
Journal:  Mov Disord       Date:  2012-09-13       Impact factor: 10.338

5.  Neuroimaging and neurophysiological evaluation of severity of Parkinson's disease.

Authors:  Tomoyoshi Kuribara; Rei Enatsu; Mayumi Kitagawa; Masayasu Arihara; Ayaka Sasagawa; Tsukasa Hirano; Hime Suzuki; Rintaro Yokoyama; Takeshi Mikami; Nobuhiro Mikuni
Journal:  J Clin Neurosci       Date:  2020-02-15       Impact factor: 1.961

6.  A comparison of visual and semiquantitative analysis methods for planar cardiac 123I-MIBG scintigraphy in dementia with Lewy bodies.

Authors:  Gemma Roberts; Joseph P M Kane; Jim J Lloyd; George S Petrides; Kim Howe; John T O'Brien; Alan J Thomas
Journal:  Nucl Med Commun       Date:  2019-07       Impact factor: 1.690

7.  Value of semiquantitative analysis for clinical reporting of 123I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane SPECT studies.

Authors:  Therese A Söderlund; John C Dickson; Elizabeth Prvulovich; Simona Ben-Haim; Paul Kemp; Jan Booij; Flavio Nobili; Gerda Thomsen; Osama Sabri; Pierre-Malik Koulibaly; Ozgur U Akdemir; Marco Pagani; Koen van Laere; Susanne Asenbaum-Nan; Jean George; Terez Sera; Klaus Tatsch; Jamshed Bomanji
Journal:  J Nucl Med       Date:  2013-03-14       Impact factor: 10.057

8.  A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis.

Authors:  Yu Iwabuchi; Masashi Kameyama; Yohji Matsusaka; Hidetoshi Narimatsu; Masahiro Hashimoto; Morinobu Seki; Daisuke Ito; Hajime Tabuchi; Yoshitake Yamada; Masahiro Jinzaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-03       Impact factor: 9.236

9.  Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies.

Authors:  Merijn Joling; Chris Vriend; Jessica J van der Zande; Afina W Lemstra; Odile A van den Heuvel; Jan Booij; Henk W Berendse
Journal:  Neuroimage Clin       Date:  2018-04-06       Impact factor: 4.881

Review 10.  Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.